Background: Chronic Myeloid Leukemia (CML) occurs due to malignant transformation of a pluripotent stem cell.  Progression is insidious from chronic to aggressive accelerated or blastic phases. Studies revealed a significant role of the tumor suppressor gene P53 in disease progression.

Objectives: To evaluate the immunohistochemical expression of mutant P53 protein in CML at different clinical phases.

   Chronic Myeloid Leukemia )CML( is a type of clonal hematopoietic stem cell disease marked by cytogenetic abnormalities induced by the growth and division of cells carrying the Philadelphia chromosome. The current research was carried out in Iraq to examine the link between Caspase 8 gene expression and Caspase 8 protein and the development of chronic myeloid leukemia (CML) in 100 samples (50 patients and 50 controls). There were differences in the expression of this gene between healthy controls and studied patients. The relationship between CML onset with age and gender was investigated in comparison to controls. The results revealed significant rises in the mean of Caspase 8 expression level (∆Ct) of patient groups in comparison

Background: Adults with Acute Myelogenous Leukemia (AML) have the lowest survival rate of all leukemias. Complete remission (CR) rate after induction therapy is about 55-85%, however 30% of patients fail to achieve remission and they remain alive only for about a year. Consolidation chemotherapy results in 5-year overall survival (OS) of about 30%.

Objectives: To study characteristics of adult patients with AML who attended Baghdad Teaching Hospital, their response to induction therapy and then to consolidation therapy, and their 5-year (OS) and disease free survival (DFS).

Results: Eleven patients who received attenuated induction therapy had a median survival of 6-8 mon

Objectives: The aim of this study was to assess the possible the association between +3061 (G>A, rs1143676) missense mutation in exon 24 of the integrin α-4 subunit (ITGA-4) gene and the response to natalizumab in a sample of Iraqi multiple sclerosis patients. Methods: A sample of 59 patients with multiple sclerosis (16 males and 43 females; mean age of 32 years; age range of 15 to 52 years) receiving natalizumab for at least 12 consecutive months were involved in the study between March and August/ 2022. The sample was categorized into two groups according to their response to natalizumab treatment (responders and non-responders). Polymerase chain reaction and Sanger’s sequencing for the extracted deoxyribonucleic acid was pe

Background: Chronic myeloid leukemia (CML) is a clonal stem disease with distinctive clinical course which is ultimately fatal. It is characterized by the presence of Philadelphia
chromosome (t 9:22).Tyrosine kinase inhibitors like imatinib mesylate as targeted therapy had revolutionized the management of CML with significant prolongation of overall survival and
decreased rate of blastic transformation.
Objective:This study will describe the experience of treating 44 Iraqi patients with chronic myeloid leukemia by imatinib at the National Hematology Centre in Baghdad.
Patients and Methods:This study included 44 Iraqi patients diagnosed in Chronic phase CML at the National Centre of Hematology in Baghdad fr

The following study was conducted to investigate the correlation between the expression of three different genes (NOB1, DDX47, CD101( with the occurrence and development of chronic myeloid leukemia (CML) in Iraq. The difference in the expression of these genes between patients and healthy controls was studied. Moreover the correlation of age and gender with CML occurrence and comparing with control was also examined. Results showed significant increases in mean of gene expression level (ΔCt) of patient groups for all genes compared to the corresponding ΔCt means in control group, also the gene expression folding (2-ΔΔCt) reflect significant differences in the expression of these genes and CD101, mRNA showed the highest level in CML pati

     Acute myeloid leukemia represents the most prevalent type of acute leukemia in adults. Mutations in the tumor protein (TP53) gene have been found in more than half of all human cancers. This study was done to investigate the relationship between TP53 gene expression and the appearance and progression of acute myeloid leukemia in Iraq. This study included 100 subjects, divided into 60 patients suffering from pre-diagnostic acute myeloid leukemia and 40 healthy individuals. The difference in TP53 gene expression between acute myeloid leukemia patients and healthy individuals has been investigated, and the gene expression of TP53 has been measured after extraction of total RNA at concentrations (15–83 n

Both type 1 diabetes and type 2 diabetes have a genetic component, with over 60 chromosomal regions related to type 1 diabetes and over 200 connected with type 2 diabetes at significant genome-wide levels. Numerous single nucleotide polymorphisms in the RETN gene and genetic variables can account for up to 70% of the variations in circulating resistin levels. The RETN polymorphism has been linked in numerous studies to obesity, insulin sensitivity, type 2 diabetes, and cerebrovascular illness. Our objective is to compare this RETN gene 3ʹ-untranslated region polymorphism in type 1 diabetes and type 2 diabetes Iraqi patients. We choose 51 type 1 diabetes and 52 type 2 diabetes patients against 50 healthy subjects (control group) to investig

Background: Acute myeloid leukemia (AML) is an adult leukemia characterized by rapid proliferation of undifferentiated myeloid precursors, leading to bone marrow (BM) failure and impaired erythropoiesis. The p53 tumor suppressor protein regulates cell division and inhibits tumor development by preventing cell proliferation of altered or damaged DNA. It orchestrates various cellular reactions, including cell cycle arrest, DNA repair, and antioxidant properties. Objectives: To investigate the relationship of P53 serum level with hematological findings, remission, and survival status in de novo AML patients. Methods: This is a cross-sectional study that enrolled 63 newly diagnosed de novo AML patients, and 15 sex- and age-matched healt